title: Survival and risk of relapse of acute lymphoblastic leukemia in a Mexican population is affected by dihydrofolate reductase gene polymorphisms.
abstract: Dihydrofolate reductase (DHFR) is the major target of methotrexate, a key component in childhood acute lymphoblastic leukemia (ALL) treatment. Polymorphisms in the gene coding for DHFR have been associated with adverse event treatment. This study evaluated the effect of the -A317G and C829T polymorphisms in the DHFR gene on survival and risk of relapse of ALL. Seventy patients with ALL and 100 healthy individuals were genotyped by the polymerase chain reaction-restriction fragment length polymorphism method. An association between the polymorphisms and the risk of relapse was found (p<0.05); patients with the -317G/G genotype were found to have an 8.55 (95% CI 1.84-39.70) higher chance of relapse and carriers of the 829T/T genotype had a 14.0 (95% CI 1.13-172.63) higher chance of relapse. Other variables, such as age and leukocyte count, were associated (p<0.05) with the risk of relapse of the disease. Individuals with the G/G and T/T genotype of the -A317G and C829T polymorphisms had poorer survival compared to other genotype groups (log-rank test; p<0.05). Although preliminary, these data seem to suggest a role for the DHFR polymorphisms in the risk of relapse of ALL and the mortality risk in these patients.
authors.affiliation: Laboratories of Molecular Biomedicine, and.
authors.forename: Yazmín
authors.initials: Y
authors.lastname: Gómez-Gómez
authors.forename: Jorge
authors.initials: J
authors.lastname: Organista-Nava
authors.forename: Mónica Virginia
authors.initials: MV
authors.lastname: Saavedra-Herrera
authors.forename: Ana Bertha
authors.initials: AB
authors.lastname: Rivera-Ramírez
authors.forename: Marco Antonio
authors.initials: MA
authors.lastname: Terán-Porcayo
authors.forename: Luz
authors.initials: L
authors.lastname: Del Carmen Alarcón-Romero
authors.forename: Berenice
authors.initials: B
authors.lastname: Illades-Aguiar
authors.forename: Marco Antonio
authors.initials: MA
authors.lastname: Leyva-Vázquez